Goldman Sachs Downgrades Johnson & Johnson (JNJ) to Sell, Sees Limited Upside

Goldman Sachs downgraded Johnson & Johnson (NYSE: JNJ) from Neutral to Sell with a price target of $72.00, saying they see limited upside.

The firm said they only see 7% upside for JNJ, versus 14% average upside for the rest of the group.

"Although JNJ has potential for improved growth, we believe this is already captured
in valuation," the analyst said. "We see JNJ as lacking transformational pipeline opportunities and less inclined to do shareholder-friendly capital allocation."

Goldman upgraded Eli Lilly (NYSE: LLY) from Sell to Neutral, as noted earlier.

For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.

Shares of Johnson & Johnson closed at $69.44 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Citi Downgrades Molson Coors (TAP) to Sell, 'Cycling 2023 Could Be a Mountain Too Hard to Climb'
• Piper Sandler Downgrades Independent Bank Group (IBTX) to Underweight, 'Expectations of Slower NII Recovery'
• Morgan Stanley Double Downgrades AU Optronics (2409:TT) (AUO) to Underweight